Related Experiment Video
Updated: May 24, 2025

08:49
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
11.0K
Targeting the secretory program of 3q-amplified lung cancers
Luis Pardo1, Jim C Norman1,2
1Cancer Research UK Scotland Institute, Glasgow, United Kingdom.
The Journal of Clinical Investigation
|March 6, 2025
Summary
Researchers found that targeting secretory pathways in 3q-amplified cancers using manganese (Mn2+) can block tumor progression. This strategy degrades Golgi integral membrane protein 4 (GOLIM4), impacting cancer cell survival and recruitment of stromal cells.
Area of Science:
- Oncology
- Cell Biology
- Cancer Research
Background:
- Targeting cancer cell proliferation is a key research area.
- Secretory programs in cancer cells influence survival, migration, and tumor stroma interactions.
- 3q-amplified cancers represent a specific group of malignancies.
Purpose of the Study:
- To investigate the functional cooperativity between Golgi-resident proteins GOLIM4 and ATP2C1 in 3q-amplified cancers.
- To explore the therapeutic potential of targeting the secretory program in these cancers.
Main Methods:
- Described functional cooperativity between Golgi integral membrane protein 4 (GOLIM4) and ATPase secretory pathway Ca2+ transporting 1 (ATP2C1).
- Utilized manganese (Mn2+) to target 3q-amplified tumors.
- Assessed the impact of Mn2+ treatment on GOLIM4 degradation and secretory blockade in mice models.
Main Results:
- Functional cooperativity between GOLIM4 and ATP2C1 was identified in coordinating secretory programs.
- Manganese (Mn2+) treatment promoted GOLIM4 degradation in targeted tumors.
- A secretory blockade was imposed, impairing tumor progression and stromal cell recruitment in mice.
Conclusions:
- The secretory program is a viable therapeutic target in 3q-amplified malignancies.
- Targeting GOLIM4 and ATP2C1 offers a promising strategy to treat tumor progression.
- This approach could lead to novel therapeutic strategies for specific cancer types.

